Research Focus

Former Employee. Research and Technology Management; NE Agency Contingent

Recent additions – View all

1. Concurrent radiation therapy (RT), ipilimumab (ipi) and/or nivolumab (nivo) on a phase 1 clinical trial

   Meeting Abstract

   Barker, C. A.; Postow, M. A.; Kronenberg, S. A.; Ma, J.; Yamada, Y.; Beal, K.; Chan, T. A.; Callahan, M. K.; Wolchok, J. D.
   International Journal of Radiation Oncology, Biology, Physics (2015)

   Fulltext@MSK | Save
2. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)

   Meeting Abstract

   Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
   Journal of Clinical Oncology (2014)

   Fulltext@MSK | Save
3. A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer

   Meeting Abstract

   Segal, N. H.; Gopal, A. K.; Bhatia, S.; Kohrt, H. E.; Levy, R.; Pishvalan, M. J.; Houot, R.; Bartlett, N.; Nghlem, P.; Kronenberg, S. A.; more...
   Journal of Clinical Oncology (2014)

   Fulltext@MSK | Save